why choose us

First received: September 04, 2022

Clinical Trial: HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Liver Cancer

Study Type: INTERVENTIONAL


Official Title: Phase II Trial of Hepatic Arterial inFusion Chemotherapy Sequential transaRterial Embolization cOmbined With leNvatinib and Tislelizumab in Unresectable Hepatocellular Carcinoma (FRONT Trial)

Brief Summary: Patients with unresectable hepatocellular carcinoma will receive hepatic arterial infusion chemotherapy (HAIC) sequential transarterial embolization combined with lenvatinib and tislelizumab.

Read more